England's National Health Service said Friday it is the first health system in the world to offer a targeted blood cancer ...

A "Trojan horse" therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world first.It can halt the blood cancer myeloma for nearly three times longer ...

Panelists discuss how autologous stem cell transplant remains essential in frontline multiple myeloma management despite improved quadruple therapy outcomes, emphasizing that current evidence still ...

A Sheffield man has become one of the first patients in the world to benefit from a pioneering therapy that could halt the ...

A retrospective study presented at the recent American Society of Clinical Oncology (ASCO) meeting suggested that patients ...

A talk with study author on a new combination of acimtamig and an allogeneic natural killer cell product that shows safety ...

The NHS in England will be the first health system in the world to roll-out a ‘trojan horse’ targeted therapy for blood cancer patients which could halt the disease’s progression by nearly three times ...

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

A total of 97 patients with relapsed or refractory multiple myeloma (RRMM), each previously treated with at least three lines of therapy and nearly all triple-class refractory, received a single ...

Among patients who received four-drug consolidation therapy, 84% had measurable residual disease (MRD)-negative status before ...

During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients ...